Journal of Clinical & Experimental Pharmacology

Long Y

Publications

• Research Article
  Telmisartan Improves Memory Impairment in a Mouse Model of Type 2 Diabetes
  Author(s): Tao DG, Dong RR, Wang C, Guang JL, Tang SS, Hu M, Long Y and Hong HTao DG, Dong RR, Wang C, Guang JL, Tang SS, Hu M, Long Y and Hong H
  
  Abstract Telmisartan, an angiotensin II type 1–receptor blocker (ARB), has been reported to exert beneficial effects on the central nervous system (CNS) in streptozotocin (STZ) - induced diabetic mice. However, the effect of telmisartan on cognitive impairment associated with type 2 diabetes is not well known. Here, we investigated the effects of telmisartan on memory impairment in a mouse model with defects in insulin sensitivity and secretion, namely highfat diet (HFD) /STZ-induced diabetic mice. Our data showed that STZ / HFD diabetic mice, characterized by hyperglycemia and hypoinsulinemia, performed poorly on Morris water maze (MWM) test. Such learning and memory impairment was accompanied by increased β -amyloid peptide 42 (Aβ42), amyloid precursor protein (APP), β-site amyloid precursor protein cleaving enz.. View More»
  DOI: 10.4172/2161-1459.1000204

  Abstract PDF